Select year
FOURTH QUARTER 2024 (Figures in parentheses refer to the corresponding period last year, unless otherwise specified). Net sales amounted to SEK 364.8 million (297.8), an increase of SEK 67.1 million, or 23% (excluding foreign exchange effects an increase of 24%). Net sales in the Pediatrics segment amounted to SEK 270.3 million (220.0), an increase of […]
(Figures in the brackets refer to the same period the previous year) During the fourth quarter of 2024, BioGaia reports growth across all regions with stronger performance in Americas and stronger than expected performance in APAC and EMEA due to order variability, in combination with robust operating margins while continuing to invest in the expansion […]
BioGaia’s (NASDAQ: BIOG) financial report for the fourth quarter of 2024 will be published at approximately 8:00 AM CET on February 12, 2025. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website. CEO Theresa […]
In line with its long-term strategy to market and sell its product through own subsidiaries in certain prioritized markets, BioGaia AB has terminated the contract with its current partner in France in accordance with terms of the contract. The company is preparing to launch the business directly through its own subsidiary in France later this […]
We are proud to launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia’s product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with […]
Antibiotic resistance is among the most pressing global health threats today. According to the World Health Organization (WHO), approximately 1.3 million people die each year from infections caused by resistant bacteria. BioGaia has participated in World AMR Awareness Week, a WHO initiative, by educating and highlighting the important role probiotics can play in combating this […]
BioGaia AB (NASDAQ: BIOG) announces that Anatom Holding AG, a Switzerland-based investment firm, has acquired 4,979,813 class B shares in BioGaia AB following the exit of EQT Public Value fund. This acquisition represents 4.9% of BioGaia’s total shares and 3.7% of the total voting rights. The transaction, which is not subject to any conditions, was […]
Be the first to know all about the latest news from BioGaia.
Subscribe
